TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02938546

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG
Description: 18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
Study: NCT01153906

Intervention type: OTHER
Intervention: Data collection
Description: New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.

Intervention type: OTHER
Intervention: Data collection
Description: New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
Study: NCT03518632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval training
Description: Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval training
Description: Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oncologic care
Description: Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.
Study: NCT01360853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
Study: NCT02077946

Intervention type: DRUG
Intervention: liraglutide
Description: No treatment given.

Intervention type: DRUG
Intervention: sitagliptin
Description: No treatment given.
Study: NCT02024841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal docetaxel
Description: Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
Study: NCT01858896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-Like Peptide- 1 (GLP-1) infusion
Description: GLP-1 infusion during experimental period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Saline Infusion
Description: Saline infusion (placebo) during experimental period
Study: NCT00781872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of autologous bone marrow derived mesenchymal stem cells
Description: 60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously
Study: NCT02549248

Intervention type: OTHER
Intervention: BAL
Description: Patients with idiopathic and non idiopathic interstitial lung diseases

Intervention type: OTHER
Intervention: BAL
Description: Patients with idiopathic and non idiopathic interstitial lung diseases

Intervention type: OTHER
Intervention: BW
Description: Patients with idiopathic and non idiopathic interstitial lung diseases

Intervention type: OTHER
Intervention: BW
Description: Patients with idiopathic and non idiopathic interstitial lung diseases

Intervention type: OTHER
Intervention: EAC
Description: Patients with idiopathic and non idiopathic interstitial lung diseases

Intervention type: OTHER
Intervention: EAC
Description: Patients with idiopathic and non idiopathic interstitial lung diseases

Intervention type: OTHER
Intervention: blood specimen
Description: Patients with idiopathic and non idiopathic interstitial lung diseases

Intervention type: OTHER
Intervention: blood specimen
Description: Patients with idiopathic and non idiopathic interstitial lung diseases

Intervention type: OTHER
Intervention: Urine specimen
Description: Patients with idiopathic and non idiopathic interstitial lung diseases

Intervention type: OTHER
Intervention: Urine specimen
Description: Patients with idiopathic and non idiopathic interstitial lung diseases
Study: NCT04636320

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced CMR
Description: Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CMR
Description: Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Exercise test ECG
Description: A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise test ECG
Description: A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Resting 12 lead ECG
Description: A resting 12 lead ECG will be performed at Day 0 visit.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Resting 12 lead ECG
Description: A resting 12 lead ECG will be performed at Day 0 visit.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 24 hour Holter ECG
Description: A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24 hour Holter ECG
Description: A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
Study: NCT03459404

Intervention type: COMBINATION_PRODUCT
Intervention: Sufentanil NanoTab PCA System
Description: 15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
Study: NCT03056729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB076
Description: Administered as single intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB076
Description: Administered as single intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB076
Description: Administered as single intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB076
Description: Administered as single intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB076
Description: Administered as single intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB076
Description: Administered as single intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as single IV infusion
Study: NCT02260895

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almond pre-test snack
Description: unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
Study: NCT02836132

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers Online

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers Online

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experience Success Virtual Reality Platform
Study: NCT00654212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endo-laparoscopic approach
Description: endoluminal stenting followed by laparoscopic resection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: open approach
Description: emergency open surgery
Study: NCT04205695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEMP (closed-ended multiport catheter) group
Description: The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OESP (open-ended single port catheter) group
Description: The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. hhe Non-Stimulating Needle and the Non-Stimulating open-ended catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia
Description: A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia
Description: A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
Study: NCT00975026

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massages ± Stretches
Description: Chair Massage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massages ± Stretches
Description: Chair Massage
Study: NCT00612989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar and O6-Benzylguanine
Description: O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar and O6-Benzylguanine
Description: O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar and O6-Benzylguanine
Description: O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose.
Study: NCT02284230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03063853

Intervention type: OTHER
Group type: OTHER
Intervention: Removal of surgical clips at day 4 post operative vs day 8 post operative
Description: Removal of surgical clips at day 4 post operative vs day 8 post operative
Study: NCT01952769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDV9300
Description: The study will be done in the following manner:~1. Evaluation of MDV9300 and radiation-~   1. Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.~  2. Cohort B -3 patiens: if no toxicity \>grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity\> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity\> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given~2. Evaluation of MDV9300 and cyclophosphamide~After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:~Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2
Study: NCT03742050

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
Study: NCT03063853

Intervention type: OTHER
Group type: OTHER
Intervention: Removal of surgical clips at day 4 post operative vs day 8 post operative
Description: Removal of surgical clips at day 4 post operative vs day 8 post operative

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Elective cesarean delivery
Description: non emergent elective cesarean delivery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Elective cesarean delivery
Description: non emergent elective cesarean delivery
Study: NCT01287598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
Study: NCT03742050

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
Study: NCT04098302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride Capsules
Description: 1 mg/day oral dutasteride (2 x 0.5 mg capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo capsules with matching appearance as Dutasteride Capsules
Study: NCT01672879

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SIM
Description: Intravenous infusion over 30 minutes every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIM
Description: Intravenous infusion over 30 minutes every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIM
Description: Intravenous infusion over 30 minutes every 2 weeks
Study: NCT03019575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
Study: NCT01489800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clear liquid diet
Description: clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
Study: NCT04029831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and Ketamine Mixture (Ketofol)
Description: Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and Ketamine Mixture (Ketofol)
Description: Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1
Study: NCT02577978

Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK posterior stabilized prosthesis

Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK Sphere prosthesis
Study: NCT04663594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WofB
Description: Online experience designed to reduce anxiety and depression and support mental health and wellbeing

Intervention type: OTHER
Group type: OTHER
Intervention: Ashmolean Website
Description: A generic museum website owned by the Ashmolean Museum of Art and Archaeology at the University of Oxford.
Study: NCT00938613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: nasal spray, one spray per nostril at time 0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nasal spray, one spray per nostril at time 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: nasal spray, one spray per nostril at time 0
Study: NCT01184976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3400
Description: Plasmid DNA delivered via IM injection with electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3400
Description: Plasmid DNA delivered via IM injection with electroporation
Study: NCT01582165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg once daily vs placebo for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Placebo once daily vs rosuvastatin for 6 months